Pfizer submits preliminary data to Health Canada for kids' COVID-19 vaccine - Action News
Home WebMail Friday, November 22, 2024, 03:51 PM | Calgary | -10.4°C | Regions Advertise Login | Our platform is in maintenance mode. Some URLs may not be available. |
Politics

Pfizer submits preliminary data to Health Canada for kids' COVID-19 vaccine

Pfizer and its partner BioNTech havesubmitted preliminary data from their trial for a COVID-19 shot for kids to Health Canada earlier than expected, the department confirmed Saturday.

There are currently no COVID-19 vaccines authorized for children under 12 years old in Canada

The NBA said earlier this week that players unable to take part at games because of their vaccination status will not be paid for those matches. (Luke Dray/Getty Images)

Pfizer and its partner BioNTech havesubmitted preliminary data from their trial for a COVID-19 shot for kids to Health Canada earlier than expected, the department confirmed Saturday.

A formal filing of the submission for authorizationof a vaccine for children is expected in mid-October, according to an email from Health Canada.

Authorization of a vaccine for children between the ages of five and 11 years old would be a major step. There are currently no COVID-19 vaccines authorized for children under 12 years old in Canada.

Earlier in the week, Pfizer submitted data on its study for a vaccine for children to the U.S. Food and Drug Administration, with a formal request for emergency use authorization there also expected in the coming weeks.

WATCH | Tam talks about vaccines for children:

Tam is asked to advise parents considering COVID-19 vaccines for children

3 years ago
Duration 4:01
A reporter asks Dr. Theresa Tam, Canada's chief public health officer, for her advice to parents considering vaccinating their children once the COVID-19 vaccine becomes available to those younger than 12.

The Pfizer vaccine, which is already authorized in teens aged 12 to 15 and fully approved for ages 16 and up in the U.S., has been shown to induce a strong immune response in the target age group in a 2,268-participant clinical trial, the companies said on Sept. 20.

For children between the ages of five and 11 in the trial, the company used doses that are one-third the amount given to adults now.

Canada's chief public health officer, Dr. Theresa Tam, told reporters last week that safety was the top priority when it came to vaccinations in children.

"For the 12 to 17 year olds, so far those programs are going well. There's no specific safety concern. I do think seeing the safety data in the younger children is of paramount importance," she said.

Timeline unclear for now

Scott Gottlieb, a former FDA commissioner andcurrent Pfizer board member, told CBC'sPower & Politicsthat the company could be approved for emergency use authorization in the U.S. by Halloween.

The approval of the Pfizer vaccine for adults took about two months from its first data submissions to Health Canada.

Canada may need to procure a separate supply of doses for children, if authorization is granted by Health Canada.

"I don't suspect it's as easy as taking what we've already got in the warehouse," said a federal official speaking to CBC News on background. "That will come from their submission to the regulator."

The federal government signed a deal in April to get more shots from Pfizer including, if necessary,the pediatric variety and reformulated booster shots for adults but deliveries of this new batch aren't expected to start until sometime in the new year.

Over76per cent of all Canadians have received at least one dose of a COVID-19 vaccine, while almost 71 per cent are fully vaccinated with two doses, according to CBC's vaccination tracker.

With files from Reuters and CBC News.

Add some good to your morning and evening.

Your daily guide to the coronavirus outbreak. Get the latest news, tips on prevention and your coronavirus questions answered every evening.

...

The next issue of the Coronavirus Brief will soon be in your inbox.

Discover all CBC newsletters in theSubscription Centre.opens new window

This site is protected by reCAPTCHA and the Google Privacy Policy and Google Terms of Service apply.